Related Experiment Video
Updated: Sep 5, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Impact of COVID-19 lockdown on exercise capacity in PAH patients
Claudia Baratto1,2, Céline Dewachter2, Sergio Caravita1,3
1Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano IRCCS Ospedale San Luca Milano Italy.
Insights
The COVID-19 lockdown reduced physical activity, negatively impacting exercise capacity in pulmonary arterial hypertension (PAH) patients. Six-minute walking tests showed a significant decrease in performance after the lockdown period.
Area of Science:
- Cardiology
- Pulmonology
- Public Health
Background:
- The COVID-19 pandemic led to global lockdowns and reduced physical activity.
- Pulmonary arterial hypertension (PAH) patients may experience decreased exercise capacity due to reduced activity, especially if frail or with chronic conditions.
Purpose of the Study:
- To assess the impact of the COVID-19 lockdown on the functional status of clinically stable PAH patients.
- To compare exercise performance in PAH patients before and after the lockdown period using the 6-minute walking test (6MWT).
Main Methods:
- An observational analysis included 63 clinically stable PAH patients.
- Patients had performed at least four 6-minute walking tests (6MWT) between 2019 and 2020.
- Exercise performance was compared before and after the COVID-19 lockdown in Belgium (March-June 2020).
Main Results:
- A mean reduction of 14 meters in 6MWT distance was observed after the lockdown (p=0.004).
- The average 6MWT distance decreased from 447m in March 2020 to 434m in June 2020, a significant loss of 13m (p=0.024).
- Reduced performance occurred despite clinical stability and no signs of disease progression.
Conclusions:
- COVID-19 lockdown-induced reduction in physical activity negatively affected exercise performance in PAH patients.
- The impact on 6MWT performance should be considered when evaluating PAH patients during or after the pandemic.
- Maintaining physical activity is crucial for preserving functional status in PAH patients.
Abstract:
The outbreak of novel coronavirus-19 disease (COVID-19) was classified as a global pandemic thanks to the rapid viral spread, and restrictive policy measures of infection containment, including "lockdown" periods and self-isolation, were first instituted in Belgium from March to June 2020. The consequent reduction in physical activity could have a negative impact on exercise capacity, especially in frail patients with pre-existing chronic diseases, such as pulmonary arterial hypertension (PAH). With the aim to define the impact of COVID-19 lockdown on functional status, we included in our observational analysis clinically stable PAH patients, who had performed at least four consecutive 6-min walking tests (6MWT) during 2019-2020, to compare their exercise performance before and after the lockdown. In the 63 patients included, a comparison between the distance covered at 6MWT after the lockdown period and the pooled mean of the previous three 6MWTs showed a mean reduction of 14 m after the lockdown (p = 0.004). Moreover, the mean distance covered at 6MWT went from 447 m in March 2020 to 434 m in June 2020, with a significant average loss of 13 m (p = 0.024). Our results showed that PAH patients were less performing at 6MWT after 3 months of reduced physical activity, despite constant clinical stability and the absence of signs of disease progression, suggesting that this confounding factor should be kept in mind when evaluating changes in 6MWT during or after COVID-19 pandemic.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Peripheral Artery Disease I: Introduction
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Peripheral Artery Disease III: Interprofessional Care

